Sage Therapeutics (SAGE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sage Therapeutics faces challenges with a 90% value drop but shows promise with Zurzuvae for postpartum depression. Click ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a ...

Sage Therapeutics, Inc. (NASDAQ:SAGE – Free Report) – Equities researchers at Wedbush issued their Q1 2026 earnings estimates for Sage Therapeutics in a report released on Wednesday ...

Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. Research analysts forecast that Sage Therapeutics will post -3.52 earnings per share for the ...

$50,000 of SAGE THERAPEUTICS lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education and awareness of mental health ...

NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the ...

NEW YORK CITY, NY / ACCESS Newswire / April 8, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. ("Sage" or "the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...